Gastrointestinal Cancers

Gastrointestinal (GI) cancers account for 26% of the global cancer incidence burden.  We aspire to transform the lives of people living with cancer, including GI cancers, by delivering life-changing and best-in-class treatments.

Latest Articles on Gastrointestinal Cancers

Two people stood with their pancreas and biliary tracts highlighted next to a clipboard

Brightline-2 trial launch in biliary tract and pancreatic cancers

Find out more about the Brightline-2 trial and our commitment to people living with biliary tract and pancreatic cancers.